Wall Street Zen Downgrades DaVita (NYSE:DVA) to Hold

DaVita (NYSE:DVA) was downgraded by stock analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Several other research firms have also weighed in on DVA. UBS Group raised their target price on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Barclays increased their price objective on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a report on Wednesday, August 5th. TD Cowen raised DaVita from a “hold” rating to a “buy” rating and raised their price objective for the company from $201.00 to $220.00 in a research note on Friday, August 7th. Weiss Ratings lowered DaVita from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday. Finally, Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, DaVita presently has an average rating of “Hold” and a consensus price target of $233.43.

DaVita Stock Down 0.1%

DVA stock opened at $178.29 on Friday. The firm has a 50 day moving average of $194.23 and a two-hundred day moving average of $187.92. DaVita has a 12 month low of $101.00 and a 12 month high of $247.49. The company has a market capitalization of $11.38 billion, a price-to-earnings ratio of 14.59, a P/E/G ratio of 0.46 and a beta of 0.83.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. The business had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm earned $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts expect that DaVita will post 14.57 EPS for the current fiscal year.

Hedge Funds Weigh In On DaVita

Institutional investors have recently made changes to their positions in the business. Fifth Third Bancorp lifted its stake in shares of DaVita by 831.4% in the first quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock valued at $5,903,000 after buying an additional 34,287 shares during the period. Assenagon Asset Management S.A. increased its stake in DaVita by 30.5% during the second quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock valued at $9,963,000 after acquiring an additional 10,477 shares during the period. SG Americas Securities LLC increased its stake in DaVita by 27.4% during the first quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock valued at $32,627,000 after acquiring an additional 45,609 shares during the period. Wealthfront Advisers LLC acquired a new position in DaVita in the 2nd quarter valued at approximately $2,357,000. Finally, Invst LLC bought a new stake in shares of DaVita in the 2nd quarter worth approximately $1,238,000. 90.12% of the stock is currently owned by institutional investors.

About DaVita

DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.